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Objective: The aim of this study was to explore Jordanian patients’ perceptions toward generic medicines and to
evaluate their opinions regarding generic substitution.
Method: A cross-sectional descriptive study involving Jordanian patients was undertaken, using a self-administrated
anonymous questionnaire. The response rate was 80% (n=400/500).
Results: The study showed that cost of medicines is high according to 83% of the patients. Most patients (92%)
preferred to be prescribed the cheapest medicine. Majority of patients (79%) believed that cost should be
considered before a drug is prescribed. Most patients (78%) accepted generic substitution and believed that it can
provide significant saving. Surveyed patients (78%) agreed that they should have the option of choosing between
generic and originator and 74% believed that physicians should give them that choice. These results showed a
significant statistical correlation with the monthly income of the patient, percentage cost they pay and number of
medicines prescribed (P<0.05).
Conclusion: The high cost of medicines in Jordan is believed to be the main driver for choosing generic medicines
Furthermore; patients have positive attitudes towards generic medicines. The involvement of patients in the
treatment decision would result in more adherence and improvement in health. The insights gained from patients
in this study will be useful to health organisations and policy makers to design a robust generic policy to use
medicines cost-effectively in Jordan.
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Introduction
Generic substitution is the practice of switching from a
prescribed originator medicine to an interchangeable
generic medicine containing the same active ingredient,
dosage form, strength at the time of dispensing [1].
Generic medicines are generally marketed under the non-
proprietary name or could be marketed as branded
generics [2], as in the case of Jordan where 97% of generic
medicines are branded [3].
The generic substitutions practice is increasingly
encouraged by health authorities throughout the world
the Jordanian Ministry of Health required doctors in
public hospitals and health clinics to prescribe generically.
However, if a brand name is prescribed, the patient gets
[4], and Jordan is no exception. n 2002, a circular from* Correspondence: k0740390@kingston.ac.uk
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distribution, and reproduction in any mediumthe formulary drug anyway, unless their physician builds a
case and receives special permission to have the brand
name dispensed. Furthermore, private health insurance
companies encourage doctors to prescribe the lowest
priced generic [5]. Nevertheless, under the current
Jordanian legislation, pharmacists are not permitted to
make any change or substitution to prescriptions, unless
the pharmacist contacts the prescriber and requests
permission for the prescribed originator medicine to be
substituted to an alternative generic medicine [6].
The use of cheaper generic medicines is often promoted
as a measure to reduce the health care expenditure on
pharmaceutical products, and provide savings to patients as
well as governments. Generally, the generic medicines are
20-90% less expensive than the innovator medicines [7].
It has been estimated that €25 billion (more than $30
billion) is the annual save made by European patients and
health care systems for using generic medicines [7].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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medicines saved American patients, taxpayers, federal and
state governments and other payers $193 billion in 2011
alone, and around $1.07 trillion over the period 2002 to
2011 [8]. A World Health Organisation (WHO) study
carried out in several developing countries including
Jordan estimated an average saving of 9% to 89% could be
made by an individual country from substituting some
originator brands to lowest-priced generics [9]. In addition
the report stipulated that the saving in Jordan could be
56% if only 11 originator medicines switched to lowest
available generics [9].
Despite the financial benefits from using generic
medicines, there are still debates regarding generic substi-
tution by patients as well as prescribers, with regards to
its effect on patients’ clinical outcomes [10-12]. A German
study found that half of the primary care patients are
sceptical about generic substitution, and 13% of the
patients reported that they had experienced new adverse
reactions [13]. On the other hand, another study revealed
that 61% of the Slovakian patients had positive views
regarding generic medicines [14]. The views in the former
study were expressed by patients who were more than
60 years of age, chronically ill, and/or without higher
education. In the latter study the respondents were pre-
dominantly aged 30 years or younger. This indicates that
patients’ socio demographic characteristics such as educa-
tional level, income and age may influence people’s
opinions of generic drugs [15].
Other factors that may influence patients’ attitudes
towards generic medicines are believed to be the physi-
cians’ prescribing behaviour and their preferences for
particular originator brand or their bias against generics
[16]. Moreover, the information given by a prescribing
physician on generic substitution was also found to be a
main driver that influences patients’ beliefs about generic
medicines and their consumptions [13,17]. Previous
studies showed that physicians and pharmacists play an
important role when patients choose between branded or
generic drugs [18-20]. Therefore efforts to promote
generic substitutions practice should be targeted first
and foremost at time of prescribing as well as dispensing
[21].
Although patient perceptions may play an important
role in medication selection, previous research revealed
that patients often do not communicate with their
physicians about their medicines preference and cost
of medications. Furthermore, several studies found that
the high out of pocket-costs can be a significant obstacle
to medical adherence with prescription medication
regimens [22-24]. However, patients can still request
generic medications at the point of the clinical encounter
or at the time of dispensing of the medication at the phar-
macy [25]. In Jordan, over 80% of the cost of medicinespurchased by the public is funded through out-of pocket
payments [26].
Patient willingness to accept a generic medicine is a core
requirement to facilitate the uptake of generic medicines
[27,28]. However, there is lack of studies which investi-
gated Jordanian patients’ perceptions about generic medi-
cines, their opinions regarding costs of medicines, and
their acceptance of generic substitution.
The aim of this study was to assess the understanding
and attitude of Jordanian patients’ towards generic
medicines, their opinions about the cost of medicines in
general, and to evaluate their perceptions about generic
substitution. The findings from this study would provide a
baseline data for establishing a robust generic medicine
policy in Jordan.
Methods
This was a cross sectional study where a questionnaire
was used to collect data from Jordanian patients whom
were targeted by visiting private and public clinics, private
and public hospitals, community pharmacies and The
National Centre for Diabetes, Endocrinology & Genetics
in Jordan. One of the researchers was available on site if
the responders need any clarification at the time of the
study.
The questionnaire was tested for face and content valid-
ity by two experts. It was further revised after pilot testing
with 20 patients. Patients were given an information sheet
translated to Arabic language by certified translator that
explained the research. The questionnaire was also trans-
lated to Arabic language by a certified translator.
The questionnaire used consisted of three sections. The
first section gave a simple definition of originator and
generic medicines with examples. The second section
evaluated the preferred prescribed medicines and the
perceptions regarding originator to generic substitution
and the costs of medicines in Jordan. The last section
characterised the respondent demographics.
The responses were framed in four point likert scale
(1 = strongly disagree, 2 = disagree, 3 = agree and 4 =
strongly agree) questions.
In this study, the sample population was Jordanian
patients with chronic medical conditions. From the 500
questionnaires which were distributed, 400 questionnaires
were completed and included in this study which gives
a response rate of 80%. The participation of patients
approached was strictly voluntary and their informed
consent was obtained. Anonymity of respondents was
preserved in the study, as names of participants were not
included.
Data was collected from 15th June 2012 to 26th August
2012. All the collected data were entered into PASW®
18.0 for descriptive analysis using descriptive statistics
techniques such as frequency and cross-tabulation and




Less than 500 JD 237 (59.25)
501-1000 JD 84 (21.00)
More than 1001 JD 79 (19.75)
Educational level
Post graduate 79 (19.75)
Bachelor degree 170 (42.50)
College 62 (15.50)
High school 89 (22.25)
Percentage paid from the prescription cost
Do not pay at all 81 (20.25)
Pay only a percentage 66 (16.50)
Pay full cost 253 (63.25)
No. of medicines in the prescription
1-3 29 (7.25)
4-6 57 (14.25)
More than 6 314 (78.50)
Chronic Medical condition
Cardio-vascular diseases 122 (30.50)
Endocrine diseases 138 (34.50)
Respiratory diseases 95 (23.75)





Very good 121 (30.25)
Excellent 55 (13.75)
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approved by the Research Ethics Committee of Kingston
University, London.
Results
Demographic characteristics of responding patients
A total of 400 responses were received, with a response
rate of 80%, the basic demographic of the responding
patients is summarised in Table 1. The sample was almost
equally distributed between male (142, 48.3%) and female
(152, 51.7%). The majority of the respondents’ monthly
income was less than 500 JD (59.25%) and holding
bachelor degree (42.5%). The respondents mostly pay full
cost of their prescription (63.25%) and have more than 6
medicines in their prescription (78.5%) (Table 1).
Patients’ views on preferred physicians’ communications
When assessing the patients’ views on preferred commu-
nication with physicians, they predominantly agreed that
the physician should ask them about their medicines pref-
erence (74%, n = 296) (Table 2). There was a significant
correlation (P < 0.05) between patients’ education level
and whether or not they prefer to be asked about their
medicines preferences (Table 3). As the education level of
the responders increased their preferences to be consulted
about their medicine choices increased.
Most of the respondents (78%, n = 312) agreed that they
should have the option of choosing between generic and
originator (Table 2). A chi-square statistic found a signifi-
cant correlation (P < 0.05) between the educational level
of the responders and whether or not they should be given
the choice between generic or originator (Table 3).
Patients with higher education levels tended to agree or
strongly agree with being given the choice.
Perceptions on generic substitution
When patients were asked if they mind the pharmacist
substituting their prescribed medicine, 75% responders
did not mind the substitution to a cheaper equivalent
(n = 300) (Table 2). In addition, most patients (78%,
n = 312) did not mind their prescribed originator medicine
being substituted to a generic one (Table 2). There was a
significant correlation (P < 0.05) between the patients’
monthly income level, percentage cost paid for the
prescription and number of medicines in the prescription
and whether or not they minded their prescribed medicine
to be substituted to a cheaper medicine or a generic.
Patients with lower income, pay more percentage of their
medicines cost, and are on a higher number of medicines
tended to accept the substitution more. The values of chi
square are shown in Table 3.
Most responders (63.5%) preferred to accept generic
substitution only upon their request (n = 254) (Table 2).
There was a significant correlation (P < 0.05) betweenpatients’ income level and number of medicines in the
prescription with their preference for generic substitution
to be based on their request (Table 3). Patients with high
income levels, and who have small numbers of medicines
in their prescription, tended to agree or strongly agree
with the substitution being upon their request only. How-
ever, there was no correlation with percentage paid from
medicines cost and the acceptance of generic substitution
upon patients’ request. Interestingly, there was no corre-
lation between the education level of the responders and
their preference to be consulted prior to originator generic
substitution.
Opinions regarding locally produced generic medicines
When assessing the patients’ views on locally produced
generic medicines, 75% of them preferred to be prescribed
Table 2 Patients’ responses to four point likert scale questions exploring their perception about generic medicines





1 Physicians should ask patients about their medicines preference. 29 (7.25) 75 (18.75) 174 (43.5) 122 (30.5)
2 Patients should have the option of choosing between generic and originator. 33 (8.25) 55 (13.75) 221 (55.25) 91 (22.75)
3 I don’t mind the pharmacist substituting the medicine I was prescribed to a
cheaper equivalent one.
8 (2.00) 92 (23.00) 235(58.75) 65 (16.25)
4 I don’t mind my prescribed medicines to be substituted from originator to generic.
(e.g. Panadol to Revanin).
6 (1.50) 82 (20.50) 228 (57.00) 84 (21.00)
5 My medicines should only be substituted from originator to generic if I request.
(e.g. Panadol to Revanin).
69 (17.25) 77 (19.25) 141 (35.25) 113 (28.25)
6 I don’t mind the pharmacist substituting my prescribed medicine to an equivalent
locally produced one.
3 (0.75) 84 (21.00) 204 (51.00) 109 (27.25)
7 I prefer to be prescribed locally produced medicines. 3 (0.75) 97 (24.25) 178 (44.50) 122 (30.50)
8 I prefer to be prescribed a well-known brand. 158 (39.50) 131 (32.75) 99 (24.75) 12 (3.00)
9 I prefer to be prescribed imported rather than local medicines. 150 (37.50) 143 (35.75) 87 (21.75) 20 (5.00)
10 Costs should be considered before a drug is prescribed. 3 (0.75) 81 (20.25) 220 (55.00) 96 (24.00)
11 I don’t mind whether my prescribed / dispensed medicine is locally produced or
imported as long as it is effective.
0 (0.00) 85 (21.25) 217 (54.25) 98 (24.50)
12 I prefer to be prescribed / dispensed the cheapest medicine available for the treatment
of my condition.
18 (4.5) 14 (3.50) 251(62.75) 117 (29.25)
13 Cost is not an issue for me as long as the medicine will treat my condition. 103 (25.75) 214 (53.50) 41 (10.25) 42 (10.50)
14 A more expensive medicine is a better one. 157 (39.25) 99 (24.75) 69 (17.25) 75 (18.75)
15 Imported medicines are better. 154 (38.50) 127 (31.75) 66 (16.50) 53 (13.25)
16 Using generic medicines would provide significant saving to me. 0 (0.00) 87 (21.75) 229 (57.25) 84 (21.00)
17 In general, medicine costs in Jordan are too high. 3 (0.75) 65 (16.25) 203 (50.75) 129 (32.25)
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did not prefer to be prescribed imported rather than local
medicines (n = 293) There was a significant correlation
(P < 0.05.) between patients’ monthly income level,
percentage cost paid for their medicines and number of
medicines in the prescription and their preference for
local medicines. Patients with low income, or more
percentage cost of medicines and have higher number of
prescribed medicines tended to agree or strongly agree
with being prescribed locally produced medicines
(Table 3). Whereas there was no correlation with the
education level of responders and their preference for
imported products or locally produced products.
When asked if imported medicines are better than locally
produced ones, 70.25% of the surveyed patients disagreed
(n = 281) (Table 2). Patients with higher education level,
lower income level, pay more percentage cost of medicines
and have higher numbers of medicines tended to disagree
with imported medicines being better than locally produced
(P < 0.05) (Table 3).
The majority of patients (72.25%, n = 289) did not prefer
to be prescribed a well-known medicine brand with
78.25% agreeing for their medicines to be substituted to a
locally produced generic one (n = 313).In general, the effectiveness of the medicines is the deter-
minant in patients preference not the manufacturer country
according to 78.75% of the responders (n = 315) (Table 2).Jordanian patients’ opinions regarding cost of the
medicines
The majority of the surveyed Jordanian patients (79%,
n = 316) agreed that the costs should be considered before
a drug is prescribed (Table 2). There was a significant
relationship (P < 0.05) between the monthly income of the
patient and percentage paid from the cost of medicine
and number of medicines in the prescriptions and their
agreement. Patients with low income level, who pay more
percentage cost of medicines or who have high number of
prescribed medicines tended to agree more that costs
should be considered before a drug is prescribed.
Patients predominantly (92%, n = 368) preferred to be
prescribed and/or dispensed the cheapest medicine avail-
able (Table 2). People with low income, high number of
medicines in their prescription tended to prefer to be pre-
scribed and/or dispensed the cheapest medicine available
for the treatment of their medical condition (P < 0.05)
(Table 3). However, there was no significant correlation
Table 3 Statistically significant correlations calculated using Chi square test between the statements on the left with
each of the demography category investigated







No. of medicines in
the prescription
Chi square value
1 Physicians should ask patients about their medicines preference. NS 158.38** NS NS
2 Patients should have the option of choosing between generic and
originator.
NS 163.53** NS NS
3 I don’t mind the pharmacist substituting the medicine I was prescribed to
a cheaper equivalent one.
52.15** NS 24.00** 42.03**
4 I don’t mind my prescribed medicines to be substituted from originator
to generic. (e.g. Panadol to Revanin).
65.12** NS 45.95** 48.84**
5 My medicines should only be substituted from originator to generic if I
request. (e.g. Panadol to Revanin).
146.12** NS NS 46.63**
6 I don’t mind the pharmacist substituting my prescribed medicine to an
equivalent locally produced one.
NS NS NS NS
7 I prefer to be prescribed locally produced medicines. 66.23** NS 36.02** 55.220**
8 I prefer to be prescribed a well-known brand. NS NS NS NS
9 I prefer to be prescribed imported rather than local medicines. 16.73* NS 16.83* 24.69**
10 Costs should be considered before a drug is prescribed. 13.83* NS 24.07** 43.41**
11 I don’t mind whether my prescribed / dispensed medicine is locally
produced or imported as long as it is effective. NS
NS NS NS
12 I prefer to be prescribed / dispensed the cheapest medicine available for
the treatment of my condition.
21.13** NS NS 177.45**
13 Cost is not an issue for me as long as the medicine will treat
my condition.
22.65** NS 40.02** 68.48**
14 A more expensive medicine is a better one. 55.06** NS NS 142.07**
15 Imported medicines are better. 21.17** 34.72** 29.26** 134.66**
16 Using generic medicines would provide significant saving to me. 13.23* NS 92.07** NS
17 In general, medicine costs in Jordan are too high. 28.59** NS 46.59** 59.87**
*:p < 0.05, **:P <0.01, NS: non statistically significant correlations found.
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preference to be prescribed or dispensed the cheapest
medicine available.
Most of the patients (79.25, n = 317) disagreed to the
statement “cost is not an issue for me as long as the medi-
cine will treat my condition” (Table 2). A Chi-Square test
of independence revealed a significant relationship
(P < 0.05) between this response and the monthly income
of the patient, the% they pay from the cost of their
medicines and the number of medicines in their prescrip-
tion. Patients with low income level, or pay full cost of
medicines or are on high numbers of medicines tended to
disagree more with the above statement (Table 3).
Most of the patients (64%, n = 256) disagreed that a
more expensive medicine is a better one. Patients with
low income level or who are on a high numbers of medi-
cines tended to disagree that a more expensive medicine
is a better one (P < 0.05) (Table 3). However, there was no
significant correlation with the percentage paid frommedicine cost or educational level and the response to the
above statement.
Patients predominantly (83%, n = 332) believed that the
medicine costs in Jordan are too high (Table 2). There was
a relationship between the monthly income of the patient,
the percentage paid from the cost of medicines and the
number of prescribed medicines and the agreement to this
statement (P < 0.05) (Table 3). Patients with low income
level, or pay more percentage cost of medicines or are on
high number of medicines tended to agree more that
medicine costs in Jordan are too high.
Saving from using generic medicines
Most of the Jordanian patients (78.25% n = 313) believed
that the use of generic medicines would provide signifi-
cant saving to them (Table 2). Patients with low income
levels, or pay more percentage cost of medicines tended
to believe that the use of generic medicines would provide
significant saving for them (P < 0.05) (Table 3). However,
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medicines in the prescription and the belief of saving by
using generic medicines.
Discussion
In this study, the majority of patients (83%) believed that
the costs of medicines in Jordan are too high. Moreover,
the costs of medicines were found to be a significant issue
for about 80% of the surveyed Jordanian patients, which
in turn might affect their adherence to treatments
[22-24,29]. These results were mostly reported by low
income patients, patients who pay for medicines, and
patients who have high number of medicines in their
repeated prescriptions.
In low income countries, the health services are believed
to be of a poor quality [30] and many of the insurance
schemes do not provide medicines benefits, or do so with
substantial co-payments [31]. Therefore, medicines are
still mainly purchased through out-of-pocket payments
[32]. Results from a study in 36 developing and middle-
income countries showed that patients purchasing
medicines in private sectors pay on average 2.6 times
more for originator brands compared to their generic
equivalent [33]. This is considered as a barrier to medi-
cines access [34]. In Jordan it was reported that over 80%
of the cost of medicines purchased by the public is funded
through out-of pocket payments 26 This was reflected in
the population of this study, where about 80% of the
surveyed patients either paid full or part costs of their
medicines.
In the current survey, just under than 80% of the
respondents agreed that costs should be considered before
a drug is prescribed. In addition, Jordanian patients
surveyed predominantly (92%) preferred to be prescribed
and/or dispensed the cheapest medicine available for the
treatment of their medical condition. Furthermore, the
results showed the high trust and confidence of Jordanian
patients in locally produced generic medicines. More than
third of the respondents preferred to be prescribed a
cheaper locally produced generic medicine rather than a
more expensive imported brand medicine. Overall, almost
80% of the patients believed that the use of generic medi-
cines would provide significant saving to them.
Most patients (78%) accepted their prescribed originator
medicine being substituted to a generic one. With 75%
and 78% accepting the pharmacist substituting their medi-
cines to a cheaper one or to locally produced generic one
respectively. This was almost the same result of a previous
study that was held in Australia where 78.5% of the
patients accepted generic substitution based on pharma-
cists’ recommendation [35]. Another study in New Jersey,
USA reported that 97% of the patients who had been of-
fered substitution had agreed to switch their therapy [19].
This also corresponds to a study in Finland in which 81%of the participants were of the opinion that cheaper
generics were effective and 85% did not consider generics
substitution as a threat to drug safety [36]. On the other
hand, a Slovakian study reported that only 50% indicated
a preference for a cheaper product [14].
In America, 66.7% of the patients requested substitution
to generic medications from doctors or pharmacists in
most or all time [37]. However, 63.5% of responders in
Jordan accepted generic substitution only upon their
request, those respondents were mainly the patients with
high monthly income, and/or have less number of medi-
cines in their repeated prescription and /or have a full
medical insurance. This would indicate that these groups
of patients are less sensitive to the cost of medications.
This study found that patients, generally, have acceptabil-
ity to generic substitution, consistent with previous studies
in Denmark, Spain and Norway where preference for the
use of generics among patients was reported [38,39].
It was reported that patients’ communication with
physicians has a key role to promote the use of generic
medicines, as their preferences are a powerful motivator
to the physicians’ prescribing behaviour [40-42]. However,
patients hardly ever communicate with their physicians
about medication choices and out-of-pocket costs of
medications [15,43]. Almost third of the patients in this
study believed that they should be involved on decisions
regarding their medicines preference, and to have the
option of choosing between generic and originator. These
beliefs were reported mainly by highly educated partici-
pants, similar findings were reported in two different
studies in Sweden, in the first study higher educated
respondents were 8 times more likely to be involved in
choosing and deciding the alternative medicines if avail-
able [44]. In the second one, 94% of the patients wanted
some involvement in medicine decision making, with
positive association between education and shared deci-
sion making [45]. Moreover, it is believed that patients
who are involved in their medicines decision are more
likely to adhere to their treatment with concomitant
improvement in health [46].
Physicians’ prescribing behaviour can also be
influenced by pharmaceutical companies through a
variety of incentives such as high-end education pro-
grams or even some cash payment for prescriptions [47].
These incentives may indirectly affect the patients, by
encouraging them to use higher priced originator-
branded products instead of equally effective, lower-cost
generics [48]. Therefore, it has generally been agreed that
patients should be involved in decisions making about
their own health and treatment all over the world
[49,50]. Therefore, The Professional Medical Body in
Jordan should develop good practice standards that
require clinicians to involve patients in treatment
choices. This could be through well-designed training
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doctors, nurses and pharmacists with patients.
From this study, it is clearly obvious that Jordanian
patients have a positive attitude towards generic medi-
cines, locally produced medicines, generic substitution,
and that they prefer to be involved in medicine treatment
selection. This would facilitate the introduction of a gen-
eric policy in Jordan which encourages the utilisation of
generic medicines through generic substitution and
generic prescribing. As a result a huge saving could be
achieved to both patients and the health care system.Conclusion
The high cost of medicines in Jordan is believed to be the
main driver for choosing generic medicines which would
lead to substantial saving as identified by the findings.
Furthermore, patients have positive attitudes towards
generic medicines in general and locally produced ones in
particular. The involvement of patients in the treatment
decision making allow them to choose the preferred medi-
cine, this would result in more adherence and improve-
ment in health.
The insights gained from patients in this study will be
useful to health organisations and policy makers to design
a robust generic policy to use medicines cost-effectively
in Jordan.
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